| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | FLNT | Common Stock | Exercise of in-the-money or at-the-money derivative security | $296 | +591K | +18.83% | $0.00* | 3.73M | Jul 5, 2024 | Held by Frost Gamma Investments Trust | F1 |
| holding | FLNT | Common Stock | 8.33K | Jul 5, 2024 | Direct |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | FLNT | Pre-Funded Warrant | Exercise of in-the-money or at-the-money derivative security | $0 | -591K | -100% | $0.00* | 0 | Jul 5, 2024 | Common Stock | 591K | $0.00 | Held by Frost Gamma Investments Trust | F1, F2, F3 |
| Id | Content |
|---|---|
| F1 | These securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole stockholder of Frost-Nevada Corporation. The reporting persons disclaim beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that any reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
| F2 | The Pre-Funded Warrants became immediately exercisable after stockholder approval of the offering of the Issuer's Pre-Funded Warrants, which approval was obtained on July 2, 2024. The binding agreement for the transaction was entered into on May 13, 2024. |
| F3 | The Pre-Funded Warrants will terminate when exercised in full. |